Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Staphylococcus Aureus Colonization in Hand Eczema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects at least 18 years of age with a clear diagnosis of moderate-to-severe hand or hand/foot dermatitis.~* Subjects must be in general good health as confirmed by a medical history.~* Subjects must be capable of understanding and willing to provide a signed and dated written voluntary informed consent before any protocol specific procedures are performed.~* At the Baseline Visit, Subjects must have a Physician's Global Assessment (PGA) of at least 3 (moderate severity).~* Subject must be willing and able to participate in the study as an outpatient, making frequent visits to the study center during the treatment and follow-up period periods and comply with all study requirements.~* If a subject is a female of childbearing potential she must have a negative urine pregnancy test prior to study treatment initiation and must agree to use an approved method of birth control during the study period (barrier, oral, injection, intrauterine). NOTE: Post-menopausal (amenorrhea for at least one year) or surgically sterile (tubal ligation and/or hysterectomy) females are categorized as non-childbearing potential.~Exclusion Criteria:~* Non-English speaking subjects~* Females who are pregnant, breast feeding, or attempting to conceive.~* Subjects with a history of known or suspected intolerance to any of the excipients of retapamulin 1% ointment or clobetasol propionate 0.05% foam.~* Subjects who have used any topical corticosteroids, topical antibiotics, topical immunosuppressants, other topical therapies (tar, calcineurin inhibitors), or phototherapy (PUVA, UVB) within eight weeks of the Baseline Visit.~* Subjects who have used any systemic corticosteroids, systemic antibiotics, or systemic immunosuppressants therapies within eight weeks of the Baseline Visit.~* Subjects with any overt signs of skin atrophy, telangiectasias, and/or striae in the target area(s).~* Subjects with any active skin malignancy.~* Subjects requiring the use of medications known to alter the course of atopic dermatitis during the study period.~* Subjects who are currently participating in or, within the previous 28 days, have participated in another study for the treatment for atopic dermatitis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Retapamulin 1% ointment (Type: ACTIVE_COMPARATOR): Retapamulin 1% ointment for 5 days AND clobetasol propionate foam for 14 days
- Placebo ointment (Type: PLACEBO_COMPARATOR): Placebo ointment for 5 days AND clobetasol propionate foam for 14 days

Based on this trial design, predict the completion outcome and termination type (if applicable).